NCT04102956View on ClinicalTrials.gov

Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

March 1, 2019

Study Completion Date

August 25, 2019

Conditions
Stroke, Acute
Interventions
DRUG

Kallikrein

HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.

Trial Locations (1)

050000

Second hospital of hebei medical university, Shijiazhuang

All Listed Sponsors
lead

The Second Hospital of Hebei Medical University

OTHER

NCT04102956 - Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients | Biotech Hunter | Biotech Hunter